MedTrace Logo

Rabeprazole Protection of Aspirin Induced Gastric Damage.

NCT00220857 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-01-11

No results posted yet for this study

Summary

To determine the effectiveness of rabeprazole in preventing or decreasing acute gastroduodenal injury caused by therapeutic doses of aspirin in a placebo-controlled, randomized, double-blind parallel group study.

Conditions

  • Normal Subjects

Interventions

DRUG

Rabeprazole

Sponsors & Collaborators

  • Temple University

    lead OTHER

Principal Investigators

  • Robert S Fisher, MD · Temple University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220857 on ClinicalTrials.gov